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Abstract:
Sensing of nutrients by chemosensory cells in the gastrointestinal tract 
plays a key role in transmitting food related signals, linking information 
about composition of ingested foods to digestive processes. In recent 
years, a number of G protein-coupled receptors (GPCR) responsive to a 
range of nutrients have been identified. Many are localised to intestinal 
enteroendocrine (chemosensory) cells, promoting hormonal and 
neuronal signalling locally, centrally, and to the periphery. The field of 
gut sensory systems is relatively new and still evolving. Despite huge 
interest in these nutrient sensing GPCR, both as sensors for nutritional 
status and targets for preventing development of metabolic diseases, 
major challenges remain to be resolved. However, the gut expressed 
sweet taste receptor, resident in L-enteroendocrine cells and responsive 
to dietary sweetener additives, has already been successfully explored 
and utilised as a therapeutic target, treating weaning related disorders in 
young animals. In addition to sensing nutrients, many GPCR are targets 
for drugs used in clinical practice. As such these receptors, in particular 
those expressed in L-cells, are currently being assessed as potential new 
pathways for treating diabetes and obesity. Furthermore, growing 
recognition of gut chemosensing of microbial-produced short chain fatty 
acids has led further attention to the association between nutrition and 
development of chronic disorders focusing on the relationship between 
nutrients, gut microbiota and health. The central importance of gut 
nutrient sensing in the control of gastrointestinal physiology, health 
promotion and gut-brain communication offers promise that further 
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therapeutic successes and nutritional recommendations will arise from 
research in this area.
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19 Abstract:
20 Sensing of nutrients by chemosensory cells in the gastrointestinal tract plays a key role in 
21 transmitting food related signals, linking information about composition of ingested foods to 
22 digestive processes. In recent years, a number of G protein-coupled receptors (GPCR) 
23 responsive to a range of nutrients have been identified. Many are localised to intestinal 
24 enteroendocrine (chemosensory) cells, promoting hormonal and neuronal signalling locally, 
25 centrally, and to the periphery. The field of gut sensory systems is relatively new and still 
26 evolving. Despite huge interest in these nutrient sensing GPCR, both as sensors for nutritional 
27 status and targets for preventing development of metabolic diseases, major challenges remain 
28 to be resolved. However, the gut expressed sweet taste receptor, resident in L-enteroendocrine 
29 cells and responsive to dietary sweetener additives, has already been successfully explored and 
30 utilised as a therapeutic target, treating weaning related disorders in young animals. In addition 
31 to sensing nutrients, many GPCR are targets for drugs used in clinical practice. As such these 
32 receptors, in particular those expressed in L-cells, are currently being assessed as potential new 
33 pathways for treating diabetes and obesity. Furthermore, growing recognition of gut 
34 chemosensing of microbial-produced short chain fatty acids has led further attention to the 
35 association between nutrition and development of chronic disorders focusing on the 
36 relationship between nutrients, gut microbiota and health. The central importance of gut 
37 nutrient sensing in the control of gastrointestinal physiology, health promotion and gut-brain 
38 communication offers promise that further therapeutic successes and nutritional 
39 recommendations will arise from research in this area.
40
Page 3 of 21
Cambridge University Press
Proceedings of the Nutrition Society
For Peer Review
3
41 Introduction
42 The intestinal epithelium is a major boundary with the outside world. Epithelial cells lining the 
43 surface of the intestinal epithelium are in direct contact with a luminal environment, the 
44 composition of which varies dramatically. It has long been recognised that the gut is capable 
45 of sensing changes in its luminal content and responding by releasing chemical signals. In 
46 1902, Bayliss and Starling(1) noted that increasing the acidity in the lumen of the small intestine 
47 elicited pancreatic secretions, and that this was mediated, not via the nervous system, but by a 
48 humoral factor produced by the gut epithelium that they termed ‘secretin’.
49 Indeed, we now know that the nerve endings that transmit signals evoked by changes in the gut 
50 luminal contents do not reach the intestinal lumen and that information about the chemical 
51 nature of the luminal contents is transmitted to neurons via enteroendocrine cells linking the 
52 gut, brain and peripheral tissues.
53 Enteroendocrine cells (EEC), scattered amongst the cells lining the intestinal epithelium are 
54 pivotal to the chemosensing pathways of the intestinal tract. They are flask-shaped, with the 
55 majority having open-type morphology with apically extended processes making direct contact 
56 with ingested nutrients and microbial products in the gut lumen. These cells respond to changes 
57 in luminal contents by releasing gut hormones into systemic circulation via their basolateral 
58 membrane domain. There are at least sixteen discrete cell types that make up the 
59 enteroendocrine family (generally named after letters of alphabet) and collectively they 
60 produce over twenty different hormones(2). These includ  cholecystokinin (CCK), peptide YY 
61 (PYY) and glucagon-like peptides 1 and 2 (GLP-1, GLP-2). CCK is released by I-cells 
62 predominantly located in the proximal intestine, whereas PYY, GLP-1 and GLP-2 are secreted 
63 mostly by L-cells residing frequently in the distal gut. However, L-cells have also been 
64 identified in the duodenum albeit in lower number than observed in jejunum and ileum(3). 
65 Secretion of CCK, GLP-1 or PYY slows down gastric emptying, as well as reducing appetite 
66 and food intake. GLP-1 also functions as an incretin hormone, stimulating insulin secretion 
67 from pancreatic β-cells, improving meal-related glycaemia. GLP-2, coproduced with GLP-1, 
68 promotes intestinal epithelial cell growth and increased nutrient absorption(4,5).
69 Although it was believed that gut hormone secretion was the result of direct EEC sensing of 
70 nutrients in the lumen of the intestine, until recently little was known about the initial molecular 
71 recognition events involved in the enteroendocrine luminal sensing.
72
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73 G protein-coupled receptors (GPCR) and intestinal nutrient sensing
74 G protein-coupled receptors (GPCR) represent the largest family of cell-surface mediators of 
75 signal transduction(6). They are encoded by about 800 different genes in humans(7), enabling 
76 cells to respond to many diverse sensory inputs. Hence, GPCR are well-established targets for 
77 almost half of all therapeutic drugs, yet many are denominated as “orphan receptors” whose 
78 physiological agonists remain unknown. As such these receptors have attracted significant 
79 attention in terms of continued identification and characterisation, with recognition that they 
80 are potential targets for novel drug discovery. With more recent evidence that nutrient sensing 
81 in the gastrointestinal tract is accomplished by a number of GPCR(8), the role of these receptors 
82 as important nutritional targets is becoming increasingly evident.
83 Nutrient-sensing GPCR are categorised as either class A or class C. GPCR belonging to class 
84 C, such as the calcium sensing receptor (CaSR) and the taste 1 family receptors (T1R) are 
85 comprised of an N-terminal signal sequence, seven transmembrane domains coupled with a 
86 large extracellular domain (Venus flytrap module) and C-terminal cytoplasmic domain. Class 
87 A receptors such as fatty acid receptors also have seven transmembrane domains, but lack the 
88 Venus flytrap module(9). In general, nutrient sensing GPCR are classified based on their α- 
89 subunits and the corresponding downstream signalling pathways they recruit. They are grouped 
90 into families Gαs, Gαi, Gαq, Gα12/13, and gustducin. The physiological effects produced by these 
91 receptors in response to nutrients are mainly mediated via cyclic adenosine monophosphate 
92 (cAMP) and Ca2+ signalling cascades. Gαs stimulates adenylate cyclase (AC) leading to an 
93 increase in intracellular concentration of cAMP. Gαi inhibits AC resulting in decreased 
94 intracellular cAMP. Gαq stimulates phospholipase C (PLC) resulting in the generation of 
95 diacylglycerol (DAG) and inositol triphosphate (IP3), which respectively activate protein 
96 kinase C (PKC) triggering Ca2+ release from intracellular stores. Gα12/13 couples to the 
97 activation of the small G-protein Rho. Gustducin, a heterotrimeric G protein and mainly a 
98 member of Gαi family, can stimulate phosphodiesterase resulting in cAMP degradation, but in 
99 parallel the co-released Gβγ subunits activate PLC-β2 leading to IP3 mediated Ca2+ release. The 
100 consequent elevation of cytoplasmic Ca2+ activates the Ca2+sensitive transient receptor 
101 potential channel M5 (TRPM5) triggering membrane depolarization and opening of voltage-
102 gated Ca2+ channels(9,10). It has also been reported that gustducin activation stimulates adenylate 
103 cyclase, increasing cAMP directly or indirectly closing basolateral K+ channels and triggering 
104 membrane depolarisation(11).
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105 Several nutrient-sensing GPCR have been identified in the intestinal epithelium. They are 
106 expressed mainly on the apical membrane domain of enteroendocrine cells and are directly 
107 activated by a variety of nutrients. These include receptors for glucose, amino acids, peptides, 
108 protein hydrolysates, calcium and both long and short chain fatty acids (Fig.1)(12). Nutrient 
109 sensing initiates a cascade of events involving hormonal and neural pathways. This culminates 
110 in functional responses that ultimately regulate vital physiological processes including food 
111 intake (appetite and satiety), nutrient digestion and absorption, intestinal barrier function, gut 
112 motility, and insulin secretion.
113 This review focuses on G protein-coupled receptors responsive to digestive products of 
114 macronutrients.
115
116 Carbohydrates
117 One of the primary functions of carbohydrates is to provide body energy. They comprise of 
118 sugars, digestible polysaccharides (such as starch) and non-digestible carbohydrates consisting 
119 of plant-based fibres and non-starch polysaccharides. In the small intestine, digestible 
120 polysaccharides are hydrolysed by pancreatic amylase and brush border membrane 
121 disaccharidases to constituent monosaccharides, glucose, galactose and fructose(13). Non-
122 digestible carbohydrates which escape digestion in the small intestine, reach the large intestine 
123 where they are fermented by gut microbiota, predominantly to short chain fatty acids.
124
125 Intestinal glucose (sweet) sensing
126 Glucose is an effective inducer of secretion of gut hormones such as GLP-1, GLP-2 and 
127 glucose-dependent insulinotropic peptide (GIP). A well- known example of gastrointestinal 
128 chemosensation (the incretin effect) is the observation that orally ingested glucose is a much 
129 more effective stimulator of insulin secretion from the pancreas than is intravenously injected 
130 glucose(14), inferring the presence of an intestinal luminal glucose sensor responsible for 
131 glucose-induced gut peptide release.
132 In 2005, we reported, for the first time, that the heterodimeric sweet taste receptor T1R2-T1R3, 
133 previously characterised in the lingual epithelium, is expressed in gut EEC, and proposed that 
134 it acts as the intestinal glucose sensor(15).
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135 Further work demonstrated that all signalling elements involved in sweet taste transduction in 
136 the gustatory buds of the tongue, T1R2-T1R3, PLCβ-2, TRPM5, α-gustducin and other 
137 associated signalling elements are co-expressed in both L- and K-EEC in human and mouse 
138 intestine(16,17). In mice in which the genes encoding for α-gustducin and T1R3 were deleted, 
139 there was a failure to secrete GLP-1 in response to luminal glucose(16,17). These knockout mice 
140 also had abnormal insulin response and prolonged elevation of postprandial blood glucose, 
141 indicating that the sweet receptor expressed in intestinal L-cells coupled to α-gustducin sense 
142 luminal glucose leading to secretion of GLP-1(16,18). More recent work(19) has confirmed and 
143 extended these studies to demonstrate that in mouse small intestine, T1R2, T1R3, α-gustducin 
144 and GLP-2 are co-expressed in the same L-enteroendocrine cells and that mouse intestine 
145 secretes GLP-2 in response to glucose(19). Moreover, this glucose-induced GLP-2 release was 
146 inhibited by gurmarin (a specific inhibitor of mouse T1R3)(20,21). Furthermore, the non-nutritive 
147 sweetener, sucralose, also induced GLP-2 release from mouse small intestine, which was again 
148 inhibited by gurmarin. However, the sweetener aspartame, that does not activate mouse T1R2-
149 T1R3(22), did not induce GLP-2 release, supporting the conclusion that the T1R2-T1R3 
150 receptor, expressed in L-cells, senses luminal glucose and sweeteners to secrete GLP-2. A 
151 number of studies(3,23,24) confirming the findings of previous reports(16,17) have demonstrated 
152 that transcripts for T1R2, T1R3, α-gustducin, TRPM5 and  GLP-1, are expressed in the mucosa 
153 of human proximal intestine. Young et al. (2009) also reported that expression of T1R2, at 
154 mRNA level, was reduced in the intestine of diabetic subjects with higher fasting blood glucose 
155 concentration(23). The magnitude of GLP-1, GLP-2 and GIP secretion, has been reported to be 
156 diminished in patients with type 2 diabetes(25). A recent work has also shown that the number 
157 of EEC, including L-cells, is reduced significantly in the intestine of morbidly obese and 
158 diabetic individuals with type 2 diabetes compared to that in healthy controls(4). Thus, the 
159 reduction in T1R2 transcript level observed in diabetics(23) may be due to a reduced number of 
160 EEC expressing T1R2 and other signalling elements required for glucose-induced GLP-1 
161 secretion. Moreover, it has been demonstrated that the intragastric administration of glucose, 
162 in healthy subjects, resulted in secretion of GLP-1 and PYY, which was significantly reduced 
163 when lactisole, the specific inhibitor of human T1R3(26) was co-administered(3,24). They have 
164 concluded that in human intestine T1R2-T1R3 is involved in glucose-induced secretion of 
165 GLP-1 and PYY, with potential consequences for reducing food intake, decreasing gut motility 
166 and increasing insulin secretion (the latter in response to GLP-1).
167
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168 Mechanisms underlying intestinal sweet sensing and glucose transport regulation 
169 One important manifestation of intestinal glucose sensing by T1R2-T1R3, expressed in L-cells, 
170 is the regulation of intestinal glucose transport.
171 The major route for transport of dietary glucose from the lumen of the intestine into absorptive 
172 enterocytes is via the brush border membrane protein, the Na+/glucose cotransporter 1, 
173 SGLT1(27,28). Absorption of glucose by SGLT1 also activates electrolyte (NaCl) and water 
174 absorption, the route used for oral rehydration therapy(29-31). SGLT1 activity and expression 
175 has been shown to be directly regulated by luminal glucose, including metabolisable, non-
176 metabolisable and membrane-impermeable glucose analogues(32-34). Furthermore, the pathway 
177 underlying monosaccharide-enhanced SGLT1 expression was via a luminal membrane glucose 
178 GPCR(34,35).
179 Recent experimental evidence has demonstrated that T1R2-T1R3 expressed in L-cells senses 
180 dietary glucose (and other natural/artificial sweeteners) resulting in secretion of GLP-2, which 
181 then, via a neuro-paracrine pathway involving the enteric nervous system, enhances the half-
182 life of SGLT1 mRNA in neighbouring absorptive enterocytes. This leads to increased activity 
183 and expression of SGLT1, and enhanced intestinal glucose absorption(19). Knocking out the 
184 genes for T1R2, T1R3, or GLP-2 receptor abolishes the ability of mouse intestine to upregulate 
185 SGLT1 expression and activity in response to luminal glucose or sweeteners(19).
186 It has been shown that the expression (and activity) of SGLT1 is enhanced in the intestine of 
187 human subjects with type 2 diabetes. This increase was shown to be independent of dietary 
188 carbohydrate intake level, or any changes in blood glucose or insulin concentration(27), and 
189 proposed to be due to alterations in the mechanisms and signalling pathways involved in 
190 regulation of SGLT1 activity and expression.
191 As noted above, the total number of EEC, the expression of T1R2 and levels of gut hormones 
192 including GLP-1, GLP-2 and GIP are all significantly reduced in the intestine of diabetic 
193 individuals(4,23,25). Thus, it appears that in type 2 diabetes deregulation of intestinal glucose 
194 sensing and downstream signalling may play a role in the observed overexpression of intestinal 
195 SGLT1.
196
197 Therapeutic potential of T1R2-T1R3
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198 Post weaning intestinal disorders are major health problems for the young. Weaning-associated 
199 diarrhoea, dehydration, and nutrient malabsorption results in high levels of mortality in farm 
200 animals worldwide. The findings that small concentrations of specific natural/artificial 
201 sweeteners are detected by the intestinal T1R2-T1R3 sweet receptor, activating the pathway 
202 leading to increased glucose, electrolyte and water absorption (oral rehydration therapy)(29), 
203 has attracted worldwide uptake of these additive sweeteners in the diet of weaning animals. 
204 This innovation has improved the health and survival rate of young animals through avoidance 
205 of intestinal disorders, thereby increasing weight, enhancing immunity and optimising feed 
206 utilisation allowing the translation of scientific discoveries to animal health and welfare 
207 benefits(31,36,37). Modulation of human intestinal T1R2-T1R3 activity may also have 
208 applications in humans by controlling glucose absorption(23).
209
210 Proteins
211 Dietary proteins are essential for growth, provision of energy and health maintenance. In the 
212 small intestine, proteins are digested by pancreatic and brush border membrane proteases to di-
213 tri-oligopeptides and amino acids. There are these products that likely target EEC stimulating 
214 secretion of a range of gut hormones including CCK, GLP-1 and PYY(38). The satiety effects 
215 associated with high-protein diets may also be mediated by sensing of the amino-acid 
216 constituents of proteins.
217
218 Intestinal sensing of protein hydrolysis products
219 Intestinal amino acid sensing
220 A number of GPCR have been identified to respond to amino acids. They belong to a sub-
221 group of C class GPCR and include CaSR, the heterodimeric umami receptor T1R1-T1R3, the 
222 goldfish 5.24 receptor and its mammalian ortholog GPCR6A, and the metabotropic glutamate 
223 receptors (mGluR).
224 CaSR is a homodimeric receptor that predominantly couples to Gαq, activating 
225 phosphatidylinositol (PI)-specific PLC and inducing mobilisation of intracellular Ca2+(39). 
226 However, it also couples to Gαs, Gαi and Gα12/13(40). CaSR is a multimodal sensor for several 
227 key nutrients, notably Ca2+ ions and L-amino acids, and is expressed abundantly throughout 
Page 9 of 21
Cambridge University Press
Proceedings of the Nutrition Society
For Peer Review
9
228 the gastrointestinal tract(39,41). Although it acts as a sensor for Ca2+ in the gut lumen, it is 
229 allosterically activated by L-amino acids; responding to aromatic, aliphatic and polar, but not 
230 to branched or positively charged, amino acids(42). CaSR is highly expressed in gastrin-
231 secreting G-, somatostatin-secreting D-(43), and CCK-secreting I-cells(44), and has been 
232 proposed to facilitate amino acid-induced secretion of these gut hormones. In studies using 
233 STC-1 cells, it was shown that extracellular presence of L-phenylalanine (Phe) induced 
234 mobilisation of intracellular Ca2+ and CCK secretion which was inhibited with the allosteric 
235 CaSR inhibitor NPS2143(45). Moreover, native intestinal I-cells from mice deficient in CaSR 
236 showed impaired L-Phe mediated Ca2+ responses and CCK release(44), indicating that CaSR 
237 plays a significant role in the chemosensing of amino acids in the GI tract.
238 GPRC6A is a Gq/11-coupled receptor widely expressed in human and rodent tissues. Being a 
239 promiscuous amino acid sensor, and expressed in the digestive system, it has been proposed to 
240 act as a candidate for sensing digested amino acids in the GI tract(43,46). It has been reported by 
241 two groups that GPRC6A is involved in L-ornithine (Orn)-induced GLP-1 release in the 
242 intestinal L-cell line GLUTag(47,48). However, Oya et al. (2013) were unable to measure L-Orn-
243 induced GLP-1 release from mixed primary cultures of mouse small intestine(48). There are 
244 equally conflicting results using GPRC6A knockout mouse models. Alamshah et al. (2016) 
245 demonstrated that L-arginine (Arg) induced secretion of PYY from both wild type and 
246 GPRC6A KO mouse primary colonic L cells(49). Jørgensen & Bräuner-Osborne (2020) 
247 addressing the in vivo relevance of these findings, administered L-Orn and L-Arg orally to the 
248 full locus and exon VI GPRC6A KO mouse models(50). Whilst there was an immediate GLP-1 
249 release that diminished over time, there were no overall differences in the ability of KO-mouse 
250 models and wild type mice to secrete GLP-1 in response to these amino acids. The authors 
251 concluded that GPRC6A, in vivo, does not play a role in GLP-1 secretion in response to basic 
252 L-amino acids(50). Further work is required to unravel the precise role of GPRC6A in intestinal 
253 chemosensing.
254
255 Taste 1 receptor 1 and receptor 3 (T1R1-T1R3).
256 In taste cells of lingual epithelium, the heterodimeric combination of T1R1 and T1R3, members 
257 of the T1R family, has been identified as a broad-spectrum L-amino acid sensor responsible 
258 for mediating perception of the savoury “umami” taste of monosodium glutamate (Glu)(22,51). 
259 In rodents and many other mammalian species, T1R1-T1R3 responds to a wide variety of L-
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260 amino acids in the millimolar range. However, the receptor is not activated by L-tryptophan 
261 (Trp)(52). The human T1R1-T1R3 complex functions as a much more specific receptor, 
262 responding selectively to monosodium glutamate and aspartic acid (as well as to the Glu 
263 analogue l-AP4)(22,51,53). The T1R1-T1R3 heterodimer, like the sweet receptor T1R2-T1R3, is 
264 expressed in EEC(15) and is coupled to gustducin for the transmission of intracellular signals(54). 
265 Using STC-1 cells and native mouse intestinal tissue it has been shown that gut expressed 
266 T1R1-T1R3 serves as an intestinal L-amino acid sensor modulating amino acid-induced CCK 
267 release(55). Using siRNA to inhibit expression of T1R1 mRNA and protein in STC-1 cells, it 
268 was demonstrated that inhibition of T1R1 expression had no effect on protein hydrolysate or 
269 peptide-induced CCK release, indicating that T1R1-T1R3 is not the intestinal sensor for 
270 peptones. However, in T1R1 knockdown STC-1 cells, there was significant decline in Phe-, 
271 leucine- and Glu-induced CCK release. Conversely, Trp- induced CCK secretion was 
272 unaffected by inhibition of T1R1 expression, in agreement with Trp not being an agonist for 
273 T1R1-T1R3(55).
274 Thus, both CaSR and T1R1-T1R3 have been recognized as intestinal L-amino acid sensors 
275 mediating CCK secretion in response to aromatic amino acids such as L-Phe(44,55). Using a 
276 range of agonists and antagonists of CaSR and T1R1-T1R3 it has been demonstrated that CaSR 
277 is an intestinal L-amino acid receptor specifically sensing aromatic amino acids, while T1R1-
278 T1R3 responds to a broad spectrum of L-amino acids provoking CCK secretion from intestinal 
279 endocrine I-cells(55).
280
281 Peptone receptor
282 The identity of the cell surface receptor(s) involved in peptone-induced CCK release remains 
283 unknown. GPCR92/93 is not a member of the C-class GPCR but has been proposed as a 
284 candidate sensor for peptones in STC-1 cells(56). Further work is required to elucidate the 
285 peptone-sensing role of this GPCR, if any, in the intestine.
286
287 Fats
288 Fats play an important role in nutrition. As well as providing 30-40% of total body energy, they 
289 also offer essential fatty acids such as linoleic (omega-6) and α-linoleic (omega-3) acid that 
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290 cannot be de novo synthesised in the body. Like other macronutrients, fats must first be digested 
291 before triggering hormone secretion and are much more effective when administered into the 
292 gut lumen than into the circulation. Fat ingestion stimulates secretion of a number of gut 
293 hormones, including CCK, GLP-1 and GIP(57). It is reported that long chain fatty acids (LCFA) 
294 inhibit gastric emptying and induce satiety(58), with short chain fatty acids (SCFA) eliciting 
295 GLP-1 and PYY secretion(59).
296 Intestinal fatty acid sensing
297 There are four principal GPCR, FFA1-FFA4, that have been officially classified as members 
298 of a free fatty acid receptor family. FFA1 (GPR40) and FFA4 (GPR120) are activated by both 
299 saturated and unsaturated medium-chain (carbon length 8-12) and longer chain (carbon chain 
300 length 14-22) fatty acids and are mainly Gαq-coupled(60). The supporting evidence that long 
301 chain fatty acid receptors contribute directly to intestinal fatty acid chemosensing is from the 
302 findings that their expression in GI tract is largely limited to the enteroendocrine cell 
303 population. The pattern of expression of FFA4 in enteroendocrine cells appears to be similar 
304 to that of FFA1. This has highlighted the need for highly selective ligands to probe their 
305 functions. Based on these observations, a number of preclinical and clinical developmental 
306 programmes have explored the therapeutic potential of agonists of FFA1. Indeed, some 
307 synthetic agonists of FFA1 have shown the capacity to improve glycaemic control in diabetes. 
308 However, questions remain in terms of sustainability of effects during long term treatment(60). 
309 There are conflicting experimental evidence relating to the roles of FFA1 and FFA4(61-63) and 
310 is not clear which one plays the more important role in enteroendocrine fatty acid sensing. 
311 Despite such concerns, the evidence suggests many positive reasons to promote FFA4 as a 
312 promising therapeutic target. They include the potential capacity to regulate GLP-1 secretion 
313 from L-cells to promote insulin release and to reduce insulin resistance via anti-inflammatory 
314 mechanisms. Thus, efforts have been made in medicinal chemistry for improving the selectivity 
315 of ligands between FFA1 and FFA4, and it is proposed that perhaps combined agonists of FFA1 
316 and FFA4 may impart greater anti-diabetic efficacy, than targeting either receptor 
317 selectively(60).
318 The short chain fatty acid (SCFA) receptors FFA2 (GPR43) and FFA3 (GPR41) have been 
319 shown, by immunohistochemistry, to be expressed in colonic L-cells. They selectively bind to 
320 and are activated by SCFA (carbon chain length 1-6), particularly acetate (C2), propionate (C3) 
321 and butyrate (C4). FFA2 responds to C2-C3 fatty acids and couples to Gαi/o as well as Gαq, 
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322 whereas FFA3 preferentially binds C3-C5 and couples only to Gαi/o. These SCFA are 
323 generated predominantly in the distal gut by microbial fermentation of non-digestible 
324 carbohydrates, such as fibre and non-starch polysaccharides. It has been reported that non-
325 digestible and fermentable dietary fibre and starch, as well as SCFA themselves, enhance GLP-
326 1 secretion(64). Moreover, the SCFA-induced release of GLP-1 from EEC appears to be 
327 mediated by FFA2(65).
328 Although also activated by the same group of SCFA as FFA2, and with a broadly similar 
329 expression profile, FFA3 is less well characterised than FFA2. To date, there have been no 
330 reports of highly selective synthetic ligands for FFA3 that target the same binding site as SCFA, 
331 and as such, detailed understanding of the function of this receptor lags behind(66). There is also 
332 significant species orthologue variation in the pharmacology of SCFA receptors in respect to 
333 their endogenous ligands, which can be translated to species selectivity of synthetic ligands 
334 targeting these receptors.
335 As alterations in population and diversity of gut microbiota are associated with dysbiosis, there 
336 is considerable interest in both prebiotic and probiotic strategies to modulate microbial 
337 populations and hence the effectiveness of SCFA production(67). Thus, the physiological role 
338 of SCFA receptors, and their relative importance, compared with other possible targets of 
339 prebiotic supplementation remains to be established.
340
341 Other free fatty acid related receptors
342 GPR84 is recognised as a receptor responsive to medium-chain fatty acids. However, it is by 
343 far the least studied and understood of the currently described receptors for fatty acids. GPR119 
344 is predominantly coupled to Gαs and is responsive to monoacylglycerols, products of 
345 triglycerides hydrolysis. It is proposed that small-molecule ligands of GPR119 increase GLP-
346 1, GIP and insulin release(68), however studies have shown these ligands have limited glucose 
347 lowering and incretin activity in subjects with type 2 diabetes(69).
348
349 Concluding remarks
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350 The nutrient sensing GPCR, expressed in EEC, play important roles in sensing the gut luminal 
351 environment, transmitting nutrient-evoked signals leading to coordination of various 
352 physiological functions such as nutrient digestion, absorption, insulin secretion and food 
353 intake.
354 Targeting the gut-expressed sweet receptor, T1R2-T1R3, with dietary sweetener additives has 
355 made a significant contribution to veterinary medicine, through enhancing absorption of 
356 glucose, electrolytes and water (oral rehydration therapy) in young animals, thereby preventing 
357 weaning-induced intestinal disorders. This strategy may also have applications for the 
358 prevention of digestive disorders in premature or newborn human infants. As many GPCR are 
359 targets for numerous drugs used in clinical practice, a number of GPCR expressed in gut 
360 chemosensory cells are currently under assessment as potential new pathways for treating 
361 diabetes and obesity. However, a number of these receptors remain poorly or incompletely 
362 characterised. It is envisaged that access to high quality and well-defined agonists/antagonists, 
363 appropriate animal models, closer collaborations between different disciplines, and true ligand 
364 selectivity/specificity will allow further expansion of this GPCR repertoire. It is predicted that 
365 with these basic criteria in place the potential for much more convincing target validation of 
366 nutrient sensing GPCR will be possible.
367 With the major role that gut nutrient sensing plays in the control of gastrointestinal physiology 
368 and gut-brain communication, it is expected that further therapeutic successes and nutritional 
369 recommendations will arise from research in this area.
370
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A schematic diagram of an enteroendocrine cell with luminal-facing nutrient sensing G protein-coupled 
receptors and downstream signalling pathways. Taken from Reimann et al. (2012)(12) with permission from 
Cell Press. 
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